MINNEAPOLIS, Aug. 29, 2025 /PRNewswire/ — Phraxis, Inc., a leader in vascular access innovation, today announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide.
The procedure, performed by Dr. Ari Kramer, Vascular Access Surgeon and early clinical pioneer of EndoForce™, took place at Spartanburg Regional Medical Center in Spartanburg, South Carolina.
EndoForce™, recently granted U.S. Food and Drug Administration (FDA) approval, is the first device of its kind designed to simplify vascular access creation by replacing hand-sewn surgical sutures with a precise, reproducible connector. The technology is compatible with all PTFE grafts and was studied extensively in the company’s pivotal clinical trial.
“Every decision we make in the OR comes back to the patient. With EndoForce™, we have a tool designed to make graft-to-vein connections more predictable and efficient. Launching the first commercial case at Spartanburg Regional is a meaningful step forward for our dialysis community,” said Dr. Ari Kramer, Vascular Access Surgeon, Spartanburg Regional Medical Center.
“This achievement is the result of more than a decade of relentless innovation, collaboration with world-class surgeons, and unwavering commitment to patient outcomes. We are proud to see EndoForce™ enter the clinical arena—where it can make a meaningful difference,” said Dr. Alex Yevzlin, Founder and Chief Executive Officer of Phraxis, Inc.
“Today represents more than a first commercial case—it’s the beginning of a new standard in vascular access surgery. Dialysis patients deserve consistent, reliable solutions, and EndoForce is designed to deliver on that promise,” added Geoffrey Beecher, Chief Commercial Officer of Phraxis, Inc.
The Spartanburg case marks the official start of U.S. commercialization for EndoForce™. Phraxis will continue to partner with leading vascular surgeons and health systems to expand availability, with additional clinical sites expected to begin cases in the coming months.
About Phraxis, Inc.
Phraxis, Inc., headquartered in Minneapolis, Minnesota, is a medical device company focused on improving vascular access for dialysis patients. Its flagship innovation, the EndoForce™ Anastomotic Connector, provides a standardized alternative to traditional graft-to-vein connections, offering surgeons efficiency and patients improved outcomes.
For more information, visit www.phraxis.com.
Media Contact:
Geoffrey Beecher
Chief Commercial Officer
Phraxis, Inc.
gbeecher@phraxis.com
SOURCE Phraxis Inc.
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…
Landover, Maryland, February 6, 2026- The UA Sprinkler Fitters Local 669 Joint Apprenticeship and Training…